This document provides a short summary of this study for a general audience. You can
find more information in the scientific summary of the study. A link to the summary is
provided at the end of this document.
Study names
Short Title: A study to see how well daprodustat works and how safe it is in Japanese
patients with renal anaemia due to chronic kidney disease who were either not on
dialysis or were on peritoneal dialysis.
Full Scientific Title: A 52-week, Phase III, open-label, multi-center study to evaluate
efficacy and safety of GSK1278863 (daprodustat) in Japanese non-dialysis and
peritoneal dialysis subjects with anaemia associated with chronic kidney disease.
Study Number: 201753
Who sponsored this study?
GlaxoSmithKline (GSK)
GSK Clinical Support Help Desk
Website: clinicalsupporthd.gsk.com/contact.html
Email: GSKClinicalSupportHD@gsk.com
General information about the clinical study
When and where was this study done?
The study started in June 2016 and ended in October 2018. All study sites were in
Japan.
What was the main objective of this study?
Patients with chronic kidney disease may develop anaemia. Anaemia is a condition that
arises because the blood does not have enough healthy red blood cells or haemoglobin
(Hgb). Haemoglobin is a protein in the red blood cells that carries oxygen to all parts of
the body.
Use of the data and information contained in this Document is unrestricted, provided that it may not
be used in applications by others for regulatory approval of a product. While not required, when using
these data, we ask that proper credit or attribution of GSK as the source of the data be given. GSK
disclaims liability for all uses of the data by users of this Document, to the fullest extent permitted by
applicable law. No trademark, patent, or regulatory/data exclusivity rights held by GSK are waived,
licensed or otherwise affected.